Clinical Trials

120 enrolled

Breast Neoplasms

NCT05823623 2023-09-14

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

30 enrolled

Breast Neoplasms

NCT05880927 2023-05-30

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

150 enrolled

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

41 enrolled

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

30 enrolled

Breast Neoplasms

NCT05764941 2023-03-27

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

59 enrolled

Breast Neoplasms

NCT04582968 2023-01-18

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Phase 1/2 Unknown

39 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03863223 2022-11-23

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Phase 3 Unknown

590 enrolled

Breast Neoplasms

NCT05621434 2022-11-18

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

63 enrolled

Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

240 enrolled

Breast Neoplasms

NCT05030519 2022-03-02

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

50 enrolled

Breast Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Breast Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

60 enrolled

Breast Neoplasms

NCT03980054 2021-05-24

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Phase 3 Unknown

1,192 enrolled

Breast Neoplasms

NCT04899128 2021-05-24

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Breast Neoplasms

NCT02500199 2021-02-01

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Phase 1 Unknown

50 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04609540 2020-12-16

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

200 enrolled

Breast Neoplasms

NCT04659499 2020-12-09

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

261 enrolled

Breast Neoplasms

NCT04639271 2020-11-20

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Neoplasms

NCT04255056 2020-02-07

PRETTY

27 enrolled

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04236310 2020-01-22

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

37 enrolled

Breast Neoplasms

NCT04095390 2019-09-19

INPHASE

60 enrolled

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

77 enrolled

Breast Diseases, Breast Neoplasms

NCT03756064 2019-08-13

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Phase NA Unknown

Breast Diseases, Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

30 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

35 enrolled

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

32 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT03412383 2018-01-30

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

14 enrolled